STI571 (imatinib mesylate; Gleevec) is the first approved medication that targets the ATP-binding region of a tyrosine kinase. Its target, BCR-ABL, is the result of a reciprocal translocation between chromosomes 9 and 22 (the Philadelphia chromosome), and is found in the leukemic cells of 495% of patients with chronic myeloid leukemia (CML) (Nowell and Hungerford, 1960; Rowley, 1973) . Clinically, CML typically progresses from an early or 'chronic phase,' during which patients are relatively asymptomatic, through an 'accelerated phase,' when increasing numbers of immature hematopoietic cells populate the bone marrow. During the subsequent terminal 'blast crisis phase,' the bone marrow becomes increasingly populated by immature blasts that fail to mature, and normal hematopoiesis is suppressed. The median time from diagnosis to blast crisis phase is approximately 5 years. While about 90% of new CML diagnoses are made in the chronic phase, the remainder are not detected until the advanced phases (accelerated and blast crisis phases).
STI571 is a small molecule that readily traverses the cell membrane and binds to the kinase domain of BCR-ABL in its closed, inactive conformation (Schindler et al., 2000) . The growth of BCR-ABL-expressing cells in vitro is inhibited by STI571 (Druker et al., 1996; Deininger et al., 1997) and cells have been documented to undergo apoptosis (Gambacorti-Passerini et al., 1997) . While its long-term efficacy remains to be established, accumulating evidence suggests that STI571 is the most effective single drug for the treatment of CML Kantarjian et al., 2002; Sawyers et al., 2002) . Its striking efficacy and generally mild side effect profile have led many clinicians as well as some experts to consider STI571 first-line therapy for most cases of CML.
The response of CML to therapeutic interventions is typically measured in two ways. Hematologic response refers to normalization of leukocyte, platelet, and erythrocyte counts. Cytogenetic response refers to diminution in the percentage of metaphases exhibiting the Philadelphia chromosome. The majority of CML patients respond to STI571, including approximately 95% of chronic phase cases. Relapse, however, is known to occur in a subset of patients, particularly those with advanced phase disease. While, to date, the relapse rate in the chronic phase is approximately 15%, nearly 100% of advanced phase cases relapse despite continuation of STI571. Significantly, BCR-ABL enzymatic activity is reinstated in the majority of patients at the time of relapse, suggesting that BCR-ABL activity remains essential for the leukemic clone (Gorre et al., 2001) . The clinical success of this tyrosine kinase inhibitor coupled with the indispensability of BCR-ABL activity at the time of relapse highlight the need to define the mechanisms of STI571 resistance and to develop novel therapeutic interventions.
In Vitro models of STI571 resistance
Initial attempts to anticipate and define possible mechanisms of resistance to STI571 utilized in vitro preclinical models of resistance. Several laboratories exposed BCR-ABL-expressing cell lines to gradually increasing concentrations of STI571 over a period of several months and were able to generate subclones with decreased sensitivity to STI571. Various mechanisms of resistance have been reported, including the presence of elevated levels of BCR-ABL as a result of genomic amplification of the BCR-ABL locus (le Mahon et al., 2000; Weisberg and Griffin, 2000) . Additionally, exposure to STI571 in one amplificationharboring resistant cell line also resulted in a significant decrease in caspase 3-like activity when compared with the parental line (le . Other mechanisms that have been implicated in resistant cell line models include: mildly increased levels of BCR-ABL protein in the absence of genomic amplification (Weisberg and Griffin, 2000) ; increased levels of Pgp multidrug resistance protein (Mahon et al., 2000) ; and failure to undergo apoptosis despite biochemical inhibition of BCR-ABL activity, suggestive of an independent survival pathway (Deininger et al., 1997) .
To address the possibility of point mutation in the BCR-ABL kinase domain leading to resistance, sequencing of the kinase domain was performed in all of the above studies, and no evidence of mutation was found. It is important to note, however, that the methodology utilized in each of the studies was subject to limitations. Two investigators Weisberg and Griffin, 2000) sequenced only a small region of the ABL kinase domain. While Mahon et al. sequenced the entire kinase domain, they, in addition to the other two groups, used PCR primers derived from ABL, which would fail to distinguish BCR-ABL from ABL. Furthermore, they performed sequence analysis on only two of their five resistant cell lines. As the majority of cell lines had some degree of BCR-ABL genomic amplification, however, it seems probable that kinase domain sequences were indeed obtained from an mRNA molecule derived from BCR-ABL rather than from c-ABL. It remains possible that only a subset of the multiple BCR-ABL genomic loci in each cell harbors point mutations, and their detection would require more sensitive methods of sequence analysis. In fact, one group has recently reported detection of a BCR-ABL kinase domain point mutation (T315I, see below) in a resistant cell line (Ricci et al., 2002) . Nonetheless, it appears that overexpression of BCR-ABL via genomic amplification may be the predominant mechanism of resistance in these models of STI571 resistance, in a manner reminiscent of DHFR gene amplification in response to increasing doses of methotrexate.
In vivo models of STI571 resistance
The first published animal model of STI571 resistance used subcutaneous injection of the human CML cell line KU812 into nude mice . Treatment of the mice with STI571 for 11 days was initiated 1, 8, and 15 days following injection. Regression of tumors was seen in all cases, but in mice in which treatment was initiated at 15 days, all eventually relapsed, suggesting that tumor burden may be an important factor for the development of relapse. Interestingly, while relapsed tumors were not responsive to retreatment with STI571, they retained sensitivity to STI571 in vitro, suggestive of an in vivo drug inactivation mechanism. The authors measured plasma concentrations of the serum protein alpha-1 acid glycoprotein (AGP), which is known to bind basic compounds. A strong correlation between plasma AGP levels and tumor load was found. Further evidence for this mechanism came from treatment of relapsed tumors in vivo with a combination of STI571 and erythromycin, which competes with STI571 for the drug-binding site on AGP. The combination of erythromycin and STI571 in this system resulted in improved antitumor activity. However, because erythromycin is a cytochrome P-450 3A4 inhibitor and is therefore predicted to decrease metabolism of STI571, its apparent synergy with STI571 in this model may not depend upon AGP. AGP purified from normal donors did not affect the growth inhibitory properties of STI571 on K562 cells in vitro. Furthermore, AGP purified from CML patients, who have significantly higher levels of the protein than healthy people, also failed to abrogate the activity of STI571 in this assay (Jorgensen et al., 2002) . While STI571 is known to be bound in human serum by both AGP and albumin, the role of increased AGP levels in STI571 resistance in CML patients remains unclear.
Studies of patient-derived cells
While in vitro and in vivo laboratory models of resistance can be informative, their relevance to mechanisms of resistance in the leukemic cells of patients being treated with STI571 is unknown. To date, several laboratories have published evidence for various mechanisms of resistance in the cells of CML patients. Mutation within the tyrosine kinase domain of BCR-ABL has been most frequently implicated. Our laboratory published the first study of STI571 resistance in cells isolated from CML patients at the time of relapse. Cells from 11 patients with advanced phase CML being treated with STI571 whose disease had relapsed after an initial response were analysed (Gorre et al., 2001) . Significantly, BCR-ABL activity, as inferred from phosphorylation of the adaptor protein Crkl, was detectable in cell lysates prior to treatment, inhibited during response to STI571, and became reactivated at the time of relapse, suggesting that BCR-ABL signaling is critical for leukemogenesis. In contrast to the mouse model described above, cells from patients remained resistant to STI571 in vitro, consistent with a cell-intrinsic mechanism of resistance. Evidence of genomic amplification was found in three cases. Six cases were found to harbor a point mutation in the kinase domain of BCR-ABL, which results in substitution of isoleucine for threonine at amino-acid position 315 (T315I). Based upon the known co-crystal structure of the ABL kinase domain with a derivative of STI571 (Schindler et al., 2000) , this substitution is predicted to abrogate affinity for the drug. Introduction of BCR-ABL containing this mutation into a human cell line resulted in marked biochemical and biological insensitivity to STI571.
Since this original report, many groups have reported finding various kinase domain mutations in the cells of relapsed CML patients at highly varying frequencies. While two groups reported kinase domain mutations in only two of 44 patients with relapsed or refractory disease (Barthe et al., 2001; Hochhaus et al., 2001) , specific details regarding methodology and patient selection, which are critical to the issue of BCR-ABL kinase domain mutation detection, were not provided. The original report by Gorre et al. utilized PCR amplification of the BCR-ABL kinase domain, subcloning of PCR products, and sequence analysis of multiple subclones. In their analysis of eight patients with Philadelphia chromosome-associated leukemia, von Bubnoff et al. performed direct sequencing of the ABL kinase domain at the time of relapse. As the PCR primers used in this study were derived from ABL sequences exclusively, there is no way of distinguishing the kinase domain of BCR-ABL from that of ABL. Furthermore, it is estimated that direct sequencing and chromatogram analysis enables the detection of sequences that comprise greater than 30% of sequences. As, in the absence of genomic amplification, ABL mRNA levels are typically equivalent to those of BCR-ABL, only approximately half of the sequences represented in a chromatogram would be predicted to represent BCR-ABL sequences. If a kinase domain mutation is present in a subpopulation of BCR-ABLexpressing cells at the time of relapse, its signal would be predicted to be further attenuated. Nonetheless, despite the theoretical limitations of this method of analysis, von Bubnoff et al. identified BCR-ABL/ABL kinase domain mutations in seven of eight patients analysed. In addition to the previously identified T315I, detected in two patients, the mutations Y253H (two patients), E255K (one patient), E255V (one patient), and H396P (one patient) were also detected. Introduction of a BCR-ABL cDNA modified to express these mutations in Ba/F3 resulted in varying degrees of resistance to the growth inhibitory properties of STI571. Another group (Hofmann et al., 2002) utilized a similar methodology to analyse BCR-ABL/ABL kinase domain mutations in nine patients with Philadelphia chromosome-associated acute lymphoblastic leukemia (ALL) who had acquired resistance to STI571. Six of nine patients were found to harbor the E255K mutation at the time of relapse, and one case of T315I was identified.
Branford et al. reported an analysis of 18 patients with relapsing CML. In contrast to the methods of von Bubnoff et al. and Hofmann et al., this group performed a two-step PCR. The first round of amplification utilized a 5
0 BCR primer and a 3 0 ABL primer to ensure amplification of the kinase domain of BCR-ABL to the exclusion of ABL. Using this fragment as a template, a second PCR was performed to focus on the kinase domain, and this PCR product was then directly sequenced. As this methodology eliminates competing ABL kinase domain sequences from analysis, it is predicted to improve significantly the sensitivity of the assay. Direct sequencing of the PCR product, however, may fail to detect mutations that comprise a minority of the total sequence. In their analysis, mutations were detected in seven of 11 patients with relapsing advanced phase CML, three of five cases of relapsed chronic phase CML, and two of two cases of Philadelphia chromosome-associated ALL. Additionally, the authors analysed 10 patients with persistence of the Philadelphia chromosome despite otherwise responsive disease (i.e., hematologic response in the absence of cytogenetic response), and detected a point mutation in one case. The most common mutation in their analysis was E255K (n ¼ 4). T315I was detected in three cases, G250E and M351T were each detected in two cases, and single examples of Y253H and F317L were also found.
Analysis of a greater number of chronic phase patients was recently reported (Roche-Lestienne et al., 2002) . These authors evaluated 16 patients with relapsing chronic phase disease and eight patients with relapsing advanced phase CML who had previously achieved hematologic responses but had obtained no cytogenetic response. The resistant clone therefore arose from a background of BCR-ABL-positive cells. Notably, these authors chose PCR primers that would not distinguish BCR-ABL from ABL, and analysed for the mutations by direct sequencing analysis. Evidence for T315I was found in one chronic phase patient and two advanced phase patients at the time of relapse. M351T was identified in one chronic phase patient, and F311L was detected in one advanced phase patient at the time of relapse. The authors utilized allele-specific oligonucleotide technology to assess for the presence of the mutations prior to treatment, and found evidence in each of the five cases for the presence of mutations prior to STI571 therapy. However, due to the methodology employed, the possibility of these mutations existing in ABL and not BCR-ABL cannot be excluded. No evidence for genomic amplification in the 24 samples was found at the time of relapse.
Our analysis of samples obtained from patients with all phases of CML with acquired resistance to STI571 was recently published (Shah et al., 2002) . In this expanded analysis, the BCR-ABL kinase domain was subjected to PCR amplification and subcloning. A total of 10 independent clones per patient were then sequenced. To reduce the likelihood that sequence variations from wild-type BCR-ABL were due to error introduced by either reverse transcriptase or thermostable DNA polymerase, mutations were only counted if they were found in two of the 10 clones. Using this method of analysis, BCR-ABL kinase domain mutations were found in 15 of 16 patients with myeloid blast crisis CML who suffered relapse, four of five patients with relapsing lymphoid blast crisis, and 10 of 11 patients with relapsing chronic phase CML. A total of 13 different amino-acid positions were found to harbor mutations at the time of relapse (Figure 1) . We also analysed the BCR-ABL kinase domain from a cohort of patients with chronic phase CML at the time of hematologic response who had no cytogenetic response to STI571, and four of 13 samples analysed revealed kinase domain mutations. Three of these four subsequently suffered hematologic relapse, and only one of nine patients with no evidence of BCR-ABL kinase domain mutation subsequently suffered relapse. Notably, this patient was found to have evidence of BCR-ABL amplification at the time of relapse. Larger studies to determine the ability of periodic sequence analysis of the BCR-ABL kinase domain to determine risk of relapse in patients who fail to have complete cytogenetic responses to STI571 are warranted. To determine if BCR-ABL kinase domain mutations could explain primary resistance to STI571, we analysed pretreatment samples from four patients with myeloid blast crisis who subsequently achieved no effective response to STI571. Four mutations were detected at low levels in two of the four patients. Interestingly, two of these mutations were known to also impart resistance to STI571, and the ability to detect mutations prior to therapy suggests that some STI571-resistant mutants may confer a biological advantage to cells that harbor them.
To assess the biochemical and biological properties of mutant BCR-ABL isoforms, we experimentally introduced the eight most frequently occurring mutations into a BCR-ABL expression construct and found that different mutations impart varying degrees of STI571 resistance in stably expressing Ba/F3 cells. Significantly, some mutant BCR-ABL isoforms were clearly sensitive to STI571 at concentrations that could possibly be achieved in patients treated with higher doses of STI571 than those currently employed. A few mutations, however, led to profound STI571 resistance in this system. Mutant amino-acid residues found in resistant cases were analysed in the context of the known crystal structure of ABL complexed with STI571. Mutations were categorized into two groups: those that are predicted to interfere directly with the ability of STI571 to bind the kinase domain, and those that presumably impair the ability of the kinase to adopt the conformation required for STI571 binding (Figure 2) .
Our methodology also provided the first evidence of polyclonal resistance in an approximately 35% of patients, where two or more alleles harboring distinct mutant BCR-ABL kinase domains could be found in a single patient (Figure 3) . Importantly, when polyclonal resistance exists, the proportion of BCR-ABL kinase domain sequences comprised by each mutation is most frequently less than 50%. Methods of detection utilizing direct sequencing might be expected to lack the sensitivity required to detect reliably mutations in this setting, particularly when the signal intensity of these sequences is further attenuated by methodology that . STI571 is depicted in gold. Amino-acid residues implicated in resistance are enumerated. Spheres 1-3 (red) represent mutations that directly affect STI571 binding. All remaining spheres are likely to affect the ability of the kinase to adopt the conformation required for binding STI571, including those in the P-loop (4-8; green) and those in the vicinity of the activation loop (9-13; cyan). The activation loop is colored purple. The positions of amino acids are as follows: 1, F317L; 2, T315I; 3, F359; 4, M244; 5, G250; 6, Q252; 7, Y253; 8, E255; 9, M351; 10, E355; 11, V379; 12, L387; 13, H396. F311 is not depicted. V379I has been detected in a patient who failed to achieve a cytogenetic response, but has thus far not been implicated in acquired resistance to STI571 (reprinted with permission of Cell Press) STI571 resistance mechanisms NP Shah and CL Sawyers fails to exclude c-ABL sequences from analysis. Differences in mutation detection methodology may therefore account for a significant proportion of the discrepant reported frequencies of BCR-ABL kinase domain mutations. In addition, one of the two groups preliminarily reporting the existence of kinase domain mutations in only two of 44 analysed cases has recently published analysis of 43 cases of acquired resistance. BCR-ABL kinase domain mutations were detected in 23 of these cases, and represented the most common mechanism of resistance in this setting. Furthermore, the T315I mutation originally described by Gorre et al.
represented the most frequently found kinase domain mutation (detected in six of the 23 cases showing evidence of kinase domain mutations) . Therefore, the emergence of BCR-ABL kinase domain mutations under the selective pressure of STI571 now appears to be generally accepted as a primary mechanism of acquired resistance to STI571 (Table 1) . Gene expression profiling of STI571-sensitive and -resistant patients with Philadelphia chromosome-associated ALL has been performed (Hofmann et al., 2002) . Bone marrow samples from 17 ALL patients were obtained prior to treatment with STI571. Of these, 10 subsequently responded, while the remainder exhibited primary resistance. The expression of 95 genes could be used to predict sensitivity to STI571. Six patients who responded and subsequently relapsed were also analysed prior to treatment and at the time of relapse. A total of 56 genes that exhibited differential expression, including Bruton's tyrosine kinase (BTK) as well as two ATP synthetases, were identified. Only one gene, glutamatecysteine ligase modifier subunit (GCLM), was present on both lists. Of note, in five of the six cases of acquired resistance, BCR-ABL/ABL kinase domain mutations were found at the time of relapse. Therefore, it is possible that these changes in gene expression reflect differences between wild-type and mutant BCR-ABL alleles rather than bypass pathways of STI571 resistance. The list of genes identified does not appear to offer any obvious clues regarding mechanisms of primary STI571 resistance. A parallel analysis of pretreatment samples from myeloid blast crisis patients led to a gene list that accurately predicted survival. While there was very little overlap between the two gene lists with the exception of a high representation of kinase-encoding genes (Graeber et al., submitted) , hypothesis-driven experiments will be required to determine the functional ramifications of these differential expression studies, as well as to validate their predictive value prospectively.
Future directions
Studies of clinical samples from CML patients with STI571 resistance have provided compelling evidence for the importance of BCR-ABL activity in all phases of the disease. When sensitive methods are used, BCR-ABL kinase domain mutations appear to be detectable in the overwhelming majority of CML patients with acquired resistance to STI571. A minority of patients exhibit genomic amplification of apparently nonmutated BCR-ABL. While it is possible that other mechanisms of resistance are contributing, future efforts to address effectively STI571 resistance must overcome the activity of BCR-ABL kinase domain mutants. The rapid rate of acquired resistance in the majority of advanced phase patients, coupled with the ability to occasionally detect kinase domain mutations prior to therapy, is supportive of a model whereby mutant BCR-ABL isoforms exist at a variable rate prior to therapy. STI571 therapy provides a powerful selective pressure for the emergence of kinase domain mutations which preserve BCR-ABL kinase activity yet abrogate drug sensitivity (Figure 3) . The underlying genetic heterogeneity of BCR-ABL coding sequences, which is predicted to be higher in advanced phases of CML when the tumor burden is larger, may thus represent the greatest barrier to the achievement of durable responses to STI571.
Hoover et al. recently presented evidence for the requirement of a critical level of BCR-ABL signal inhibition to induce apoptosis, and showed that SCH66336, a farnesyl transferase inhibitor (FTI), is capable of inducing apoptosis when combined with STI571 in cell lines that are resistant to STI571 as a result of genomic amplification. While cells engineered to express the highly STI571-resistant T315I mutant of BCR-ABL were not sensitive to the FTI, it remains possible that mutant BCR-ABL isoforms with lower degrees of STI571 resistance may retain sensitivity to the combination of FTI and STI571. It is hoped that the use of STI571 in combination with one or more additional molecular therapies will be even more successful in achieving durable responses in a manner similar to the success of combination antiretroviral therapy for HIV. Future efforts should focus on the identification and development of molecular agents with cytotoxic activity against BCR-ABL-expressing cells that is not diminished by the numerous STI571-resistant BCR-ABL kinase domain mutations identified to date. 
